Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
European phase 2 study of rHuPH20-facilitated subcutaneous immune globulin in primary immunodeficiency diseases
2012-000481-38Phase 2Terminated
- Sponsor
- Baxter International Inc.
- Start
- Apr 2012
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of subcuvia and hyaluronidase in Immunogenetic disorder and Primary antibody deficiency (PAD), sponsored by Baxter International Inc. Primary endpoint: Tolerability of rHuPH20-facilitated subcutaneous immunoglobulin treatment. Started Apr 2012; status: terminated.
02
Drugs
subcuviahyaluronidase
03
Conditions
Immunogenetic disorderPrimary antibody deficiency (PAD)
Beyond the preview
Go deeper on 2012-000481-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000481-38.